Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.44 |
| ▸ | KLK1 | P06870 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 1/20 | 0.37 |
| ▸ | ATP4B | P51164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045693 | 0.94 | HTR2A (0.45) | HTR2AHTR2CSLC6A4KLKB1KLK1 | |
| SCHEMBL5043561 | 0.94 | HTR2A (0.45) | HTR2AHTR2CSLC6A4KLKB1KLK1 | |
| SCHEMBL5044023 | 0.94 | HTR2A (0.44) | HTR2AHTR2CSLC6A4KLKB1KLK1 | |
| SCHEMBL5047859 | 0.94 | HTR2A (0.49) | HTR2AHTR2CSLC6A4KLKB1KLK1 | |
| SCHEMBL5047031 | 0.92 | HTR2A (0.43) | HTR2AHTR2CSLC6A4KLKB1KLK1 | |
| SCHEMBL5043875 | 0.92 | ALDH1A1 (0.47) | HTR2AHTR2CSLC6A4KLKB1KLK1 | |
| SCHEMBL5043802 | 0.91 | TP53 (0.46) | HTR2AHTR2CSLC6A4LMNATP53 | |
| SCHEMBL5048633 | 0.91 | HTR2A (0.49) | HTR2AHTR2CSLC6A4KLKB1KLK1 | |
| SCHEMBL5044794 | 0.91 | AR (0.43) | HTR2AHTR2CSLC6A4KLKB1KLK1 | |
| SCHEMBL5048559 | 0.90 | ALDH1A1 (0.47) | HTR2AHTR2CSLC6A4KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583762-B1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | claimed |
| US-7135488-B2 | Pyrrolyl-thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | claimed |
| EP-1583762-A1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | claimed |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2004-07-29 | — | — | US | claimed |
| WO-2004060888-A1 | NOVEL CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | claimed |
| EP-1583762-B1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| CN-100360527-C | CB 1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | CN | disclosed |
| US-7135488-B2 | Pyrrolyl-thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| CN-1735611-A | CB 1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
| EP-1583762-A1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004060888-A1 | NOVEL CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | CNR1, CNR2, NPY1R | HTR2A 602/4885HTR2C 274/4885SLC6A4 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.